Biogen Inc. (BIIB) announced on Tuesday its collaboration with Beckman Coulter, Inc. and Fujirebio to develop blood-based biomarkers for detecting tau pathology in the brain, with the prospect of advancing and potentially commercializing new tests for tau pathology in Alzheimer's disease.
The objective of this partnership is to create and advance clinical tools that can measure brain tau pathology, which could be instrumental in patient stratification and monitoring treatment responses during Alzheimer's disease clinical trials.
Jane Grogan, Head of Research at Biogen, stated, "This collaboration aims to combine our extensive scientific expertise in biomarker development with our partners' diagnostic capabilities, potentially expediting the timeline for creating blood-based diagnostics that assess a patient's level of tau pathology."
As of now, Biogen's stock is trading at $216.82, reflecting a 1.11 percent increase on the Nasdaq.
